Taysha Gene Therapies (TSHA) Return on Sales: 2022-2025
Historic Return on Sales for Taysha Gene Therapies (TSHA) over the last 3 years, with Sep 2025 value amounting to -14.96%.
- Taysha Gene Therapies' Return on Sales fell 675.00% to -14.96% in Q3 2025 from the same period last year, while for Sep 2025 it was -14.96%, marking a year-over-year decrease of 675.00%. This contributed to the annual value of -10.15% for FY2024, which is 537.00% down from last year.
- Latest data reveals that Taysha Gene Therapies reported Return on Sales of -14.96% as of Q3 2025, which was down 39.06% from -10.76% recorded in Q2 2025.
- Taysha Gene Therapies' 5-year Return on Sales high stood at 43.71% for Q4 2022, and its period low was -84.37% during Q1 2023.
- Its 3-year average for Return on Sales is -17.54%, with a median of -10.76% in 2025.
- In the last 5 years, Taysha Gene Therapies' Return on Sales tumbled by 4,849bps in 2023 and then soared by 7,879bps in 2024.
- Quarterly analysis of 4 years shows Taysha Gene Therapies' Return on Sales stood at 43.71% in 2022, then crashed by 4,849bps to -4.78% in 2023, then crashed by 537bps to -10.15% in 2024, then plummeted by 675bps to -14.96% in 2025.
- Its Return on Sales stands at -14.96% for Q3 2025, versus -10.76% for Q2 2025 and -11.36% for Q1 2025.